Heart Failure Clinical Trials in Orlando, Florida

11 studies are recruiting for heart failure in Orlando, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

   Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

   Stage

   Phase 3

   Ages

   40 and older

   Site

   Research Site, Orlando, Florida

   Locations

   957 in total

   Run by

   AstraZeneca

   See if you can join NCT06677060 on ClinicalTrials.gov

2. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

   The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

   Stage

   Not phased

   Ages

   18 to 100

   Site

   Advent Health, Orlando, Florida

   Locations

   47 in total

   Run by

   BrioHealth Solutions, Inc.

   See if you can join NCT06310031 on ClinicalTrials.gov

3. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

   The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   AdventHealth, Orlando, Florida

   Locations

   205 in total

   Run by

   Cytokinetics

   See if you can join NCT06736574 on ClinicalTrials.gov

4. Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure

   The primary purpose for this study is to support the hypothesis (pilot data) that the use of the Sensinel CPM system reduces the rate of HF-related events and the related healthcare cost. The study will also measure the impact on quality of care and patient satisfaction. In order to support the pri…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Orlando Health, Orlando, Florida

   Locations

   7 in total

   Run by

   Analog Device, Inc.

   See if you can join NCT05650541 on ClinicalTrials.gov

5. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cardiovascular Institute of Orlando, Orlando, Florida

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov

6. Alleviant ALLAY-HF Study

   Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

   Stage

   Not phased

   Ages

   40 and older

   Site

   Advent Health Orlando, Orlando, Florida

   Locations

   93 in total

   Run by

   Alleviant Medical, Inc.

   See if you can join NCT05685303 on ClinicalTrials.gov

7. Assessment of CCM in HF With Higher Ejection Fraction

   The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

   Stage

   Not phased

   Ages

   18 and older

   Site

   AdventHealth Orlando, Orlando, Florida

   Locations

   105 in total

   Run by

   Impulse Dynamics

   See if you can join NCT05064709 on ClinicalTrials.gov

8. A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

   This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by cha…

   Stage

   Phase 2

   Ages

   40 to 84

   Site

   AdventHealth Orlando, Orlando, Florida

   Locations

   117 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06979362 on ClinicalTrials.gov

9. CCM OPEN HF Registry

   The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.

   Stage

   Not phased

   Ages

   18 and older

   Site

   AdventHealth Orlando, Orlando, Florida

   Locations

   28 in total

   Run by

   Impulse Dynamics

   See if you can join NCT07112924 on ClinicalTrials.gov

10. The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

    The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).

    Stage

    Not phased

    Ages

    18 and older

    Site

    Advent Health Hospital, Orlando, Florida

    Locations

    92 in total

    Run by

    Cardiac Dimensions, Inc.

    See if you can join NCT03142152 on ClinicalTrials.gov

11. Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because …

    Stage

    Phase 3

    Ages

    18 to 75

    Site

    AdventHealth, Orlando, Florida

    Locations

    19 in total

    Run by

    Alessandro Doria

    See if you can join NCT06217302 on ClinicalTrials.gov